SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Equities researchers at HC Wainwright decreased their FY2023 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a note issued to investors on Monday, January 8th. HC Wainwright analyst E. White now anticipates that the company will earn ($4.03) per share for the year, down […]
HC Wainwright restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock, up from their previous target price of $1.00. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2023 […]
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Analyst Ratings This is a summary of […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 306,500 shares, a drop of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio […]